Dataset Information

Breast Cancer 2012 - New Aspects.

ABSTRACT: Treatment options as well as the characteristics for therapeutic decisions in patients with primary and advanced breast cancer are increasing in number and variety. New targeted therapies in combination with established chemotherapy schemes are broadening the spectrum, however potentially promising combinations do not always achieve a better result. New data from the field of pharmacogenomics point to prognostic and predictive factors that take not only the properties of the tumour but also inherited genetic properties of the patient into consideration. Current therapeutic decision-making is thus based on a combination of classical clinical and modern molecular biomarkers. Also health-economic aspects are more frequently being taken into consideration so that health-economic considerations may also play a part. This review is based on information from the recent annual congresses. The latest of these are the 34th San Antonio Breast Cancer Symposium 2011 and the ASCO Annual Meeting 2012. Among their highlights are the clinically significant results from the CLEOPATRA, BOLERO-2, EMILIA and SWOG S0226 trials on the therapy for metastatic breast cancer as well as further state-of-the-art data on the adjuvant use of bisphosphonates within the framework of the ABCSG-12, ZO-FAST, NSABP-B34 and GAIN trials.

SUBMITTER: Kolberg HC

PROVIDER: S-EPMC4168404 | biostudies-literature | 2012 Jul

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Breast Cancer 2012 - New Aspects.

Kolberg H-C HC Lüftner D D Lux M P MP Maass N N Schütz F F Fasching P A PA Fehm T T Janni W W Kümmel S S

Geburtshilfe und Frauenheilkunde 20120701 7

Treatment options as well as the characteristics for therapeutic decisions in patients with primary and advanced breast cancer are increasing in number and variety. New targeted therapies in combination with established chemotherapy schemes are broadening the spectrum, however potentially promising combinations do not always achieve a better result. New data from the field of pharmacogenomics point to prognostic and predictive factors that take not only the properties of the tumour but also inhe ...[more]

PMID: 25324576

Similar Datasets

Project description:Introduction: In spite of the existence of guidelines and international recommendations, many aspects in the diagnosis, therapy and follow-up of patients with cervical cancer are not based on validated data. A broad spectrum of different opinions and procedures concerning the therapy for patients with cervical cancer is under controversial discussion by the responsible gynaecologists in German hospitals. Methods: The present study is intended to picture the current treatment situation for cervical cancer in Germany. For this purpose a specially developed questionnaire with questions divided into 19 subsections was sent to all 688 gynaecological hospitals in Germany. Results: The response rate to the questionnaire was 34?%. 91?% of the hospitals treated between 0 and 25 patients with cervical cancer per year. 7.5?% treated between 26 and 50 and 1.4?% of the hospitals more than 50 patients per year. The bimanual examination was the most frequently used staging method (98?%); PET-CT was the least used staging method (2.3?%). Interestingly 48?% of the hospitals used surgical staging. The great majority of the hospitals (71?%) used abdominal radical hysterectomy (Wertheim-Meigs operation) to treat their patients. TMMR via laparotomy was used by 13?%. 16?% of the hospitals performed laparoscopic or robot-assisted radical hysterectomies. The sentinel concept was hardly used even in the early stages. It must be emphasised that in 74?% of the hospitals radical hysterectomies were performed even in cases with positive pelvic lymph nodes and in 43?% also in cases with positive paraaortic lymph nodes. The therapy of choice for FIGO IIB cancers is primary radiochemotherapy (RCTX) in 21?% of the hospitals; operative staging followed by radiochemotherapy in 24?% and treatment by radical hysterectomy followed by adjuvant RCTX was employed in this situation by 46?% of the hospitals. In 15-97?% of the hospitals for node-negative and in sano resected patients in stage pT1B1/1B2 after radical hysterectomy, an adjuvant RCTX is recommended when further risk factors exist (LVSI, tumour >?4?cm, age <?40 years, adenocarcinoma, S3). Conclusion: A broad spectrum of differing staging and therapy concepts is in use for patients with cervical cancer in Germany. A standardisation of therapy is needed. An update of national guidelines could help to achieve more transparency and a standardisation of treatment for patients with cervical cancer.

Dataset Information

Breast Cancer 2012 - New Aspects.

Publications

Breast Cancer 2012 - New Aspects.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets